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A b s t r a c t
We evaluated quantitative hepatitis B surface 
antigen (qHBsAg) assays and a hepatitis B virus 
(HBV) core–related antigen (HBcrAg) assay. A total 
of 529 serum samples from patients with hepatitis B 
were tested. HBsAg levels were determined by using 
the Elecsys (Roche Diagnostics, Indianapolis, IN) 
and Architect (Abbott Laboratories, Abbott Park, 
IL) qHBsAg assays. HBcrAg was measured by using 
Lumipulse HBcrAg assay (Fujirebio, Tokyo, Japan). 
Serum aminotransferases and HBV DNA were 
respectively quantified by using the Hitachi 7600 
analyzer (Hitachi High-Technologies, Tokyo, Japan) 
and the Cobas AmpliPrep/Cobas TaqMan test (Roche). 
Precision of the qHBsAg and HBcrAg assays was 
assessed, and linearity of the qHBsAg assays was 
verified. All assays showed good precision performance 
with coefficients of variation between 4.5% and 5.3% 
except for some levels. Both qHBsAg assays showed 
linearity from 0.1 to 12,000.0 IU/mL and correlated 
well (r = 0.9934). HBsAg levels correlated with HBV 
DNA (r = 0.3373) and with HBcrAg (r = 0.5164), and 
HBcrAg also correlated with HBV DNA (r = 0.5198; 
P < .0001). This observation could provide impetus for 
further research to elucidate the clinical usefulness of 
the qHBsAg and HBcrAg assays.
Hepatitis B virus (HBV) is a common pathogen, and it 
causes acute and chronic hepatitis, liver cirrhosis, and hepato-
cellular carcinoma. Hepatitis B surface antigen (HBsAg) was 
first identified more than 45 years ago1 and has been used as a 
serologic marker for the diagnosis of HBV infection. Numer-
ous assays for detecting HBsAg are commercially available, 
although most of them are intended only for qualitative or 
semiquantitative use.
In the late 1990s, the first quantitative HBsAg (qHB-
sAg) assay was developed for use with the Architect auto-
mated analyzer (Abbott Laboratories, Abbott Park, IL).2 
The clinical usefulness of this assay (Architect HBsAg QT) 
had not been extensively investigated until quite recently. 
Recent research has focused on investigating the correlation 
between HBsAg and HBV DNA levels according to the 
phases of the disease.3-5
HBsAg is known to be produced by the translation of 
transcriptionally active intrahepatic covalently closed circu-
lar DNA (cccDNA), which has a role as a template in viral 
replication and translation of virus genes transcribed from 
the integrated HBV DNA in the host genome.3,6,7 The serum 
HBsAg level was correlated with transcriptionally active 
cccDNA in previous studies and is regarded as a surrogate 
marker of infected cells.5,8 HBsAg, as the name suggests, is a 
component of the envelope of infectious virions. In addition, 
HBsAg is also found in the noninfectious form of spheres 
or filaments, which is produced at least 100-fold more than 
infectious particles.9
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Although it is considered the most accurate marker for the 
number of infected hepatocytes, measuring cccDNA can be 
done only in hepatic tissues with complex techniques. To com-
plement this limitation of cccDNA, serum HBV DNA quanti-
fication using polymerase chain reaction is widely used in cur-
rent clinical practice for the diagnosis and monitoring of HBV 
infection. A decline of the serum HBV DNA level can reflect 
a reduction in viral replication, while a decrease in the serum 
HBsAg level usually represents a reduction in the translation of 
messenger RNA molecules transcribed from cccDNA.5 Thus, 
a quantitative determination of the HBsAg level may provide 
helpful information on infection status that is complementary to 
information provided by the HBV DNA level.5
HBsAg was first proposed as a marker for monitoring 
responses to the interferon therapies in patients with chronic 
hepatitis B (CHB) in 1994,10 but at that time, the absence of 
commercially available qHBsAg assays restricted its applica-
tion as a monitoring tool. As technology has developed, qHB-
sAg assays have been improved, and their clinical usefulness 
is under investigation. Inactive HBV carriers could be dis-
criminated from patients with reactivated disease by qHBsAg 
and HBV DNA levels,11 and qHBsAg seems to be helpful for 
predicting responses to treatment with pegylated interferon 
and/or oral nucleoside/nucleotide analogs.12-14
The measurement of serum HBV core antigen (HBcAg) 
levels has been problematic because it is localized to the infect-
ed hepatic tissues and not released into blood. A new assay 
for measuring HBV core–related antigen (HBcrAg), which 
consists of a core, e antigen (HBeAg), and the precore proteins 
of HBV (22-kD precore fragment, amino acids 28-150), was 
developed; HBcrAg levels correlated well with HBV DNA 
levels.15 A recent study showed that the serum HBcrAg con-
centration was related to the level of intrahepatic cccDNA.16
Until recently, only 1 commercial qHBsAg assay had 
been available for more than a decade. The analytic perfor-
mance of the novel HBcrAg assay and of the 2 commercially 
available qHBsAg assays has not been sufficiently evaluated in 
clinical laboratories. Verifying the laboratory performance of 
these assays should precede their general application in clini-
cal practice. The aim of this study was to evaluate the analytic 
performance of 2 currently available qHBsAg assays and to 
compare the results between the assays and between those of 
other parameters, including serum HBV DNA levels. We also 
evaluated the precision performance of the newly developed 
HBcrAg assay and compared the concentrations of serum 
HBcrAg with those of HBsAg and HBV DNA.
Materials and Methods
Specimens for Comparison Between Assays
This study was approved by the institutional review 
board of Severance Hospital, Seoul, Korea. During March 
to April 2010, a total of 529 serum samples from different 
patients with CHB, regardless of treatment, were consecutive-
ly collected at the Severance Hospital. These specimens were 
requested for HBV DNA quantification by the Division of 
Hepatology, Department of Internal Medicine, to screen HBV 
infection or to monitor CHB. All specimens were divided into 
aliquots immediately after arrival, and each was assayed for 
HBV DNA, aspartate aminotransferase (AST), and alanine 
aminotransferase (ALT) levels. Remaining aliquots were 
stored at –70°C until tested, and with these aliquots, HBsAg 
and HBcrAg levels of all 529 samples were determined by the 
respective assays following the manufacturers’ instructions.
qHBsAg assays
Two methods were used for quantifying HBsAg lev-
els. One used the Roche Cobas e 411 analyzer with Elecsys 
HBsAg II Quant reagent kits (Roche Diagnostics, Indianapo-
lis, IN). This test uses the electrochemiluminescence immuno-
assay with a sandwich complex formed from the 2 biotinylated 
monoclonal anti-HBsAg antibodies and a mixture of mono-
clonal and polyclonal anti-HBsAg antibodies labeled with a 
ruthenium complex as a chemiluminescence molecule. The 
resulting chemiluminescence reactions were measured and 
converted to HBsAg concentrations in the specimens using 
the calibration curve generated by 2-point calibrators. The 
total assay duration was 18 minutes. The analyzer provided an 
onboard dilution function, which prediluted the samples auto-
matically after they were loaded; the analytic measurement 
range (AMR) suggested by the manufacturer is between 5 and 
13,000 IU/mL when the samples are 100-fold diluted using 
the automated dilution function. Diluted samples with HBsAg 
levels less than 5 IU/mL were retested without predilution, and 
the specimens were manually diluted by 20-fold before being 
loaded on the analyzer (total dilution, 2,000-fold) when the 
HBsAg concentration was greater than 13,000 IU/mL.
The other method used the Abbott Architect i4000SR 
analyzer and the Architect HBsAg QT reagents (Abbott Labo-
ratories). This assay uses a chemiluminescent microparticle 
immunoassay principle with 2-point calibration. The total 
assay time was about 35 minutes, and the AMR of this assay 
proposed by the manufacturer is from 0 to 250 IU/mL. All 
samples were tested after a 500-fold manual dilution with the 
diluent provided, which is recommended by the manufacturer. 
The serum samples with HBsAg levels greater than 125,000 
IU/mL were retested in a 1,000-fold manual dilution, and 
the samples with an HBsAg level less than 250 IU/mL were 
assayed again without dilution.
HBcrAg assay
HBcrAg in the serum samples was quantified by using 
the Lumipulse G1200 automated analyzer with the Lumipulse 
HBcrAg reagent kits (Fujirebio, Tokyo, Japan). This assay 
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uses the chemiluminescent enzyme immunoassay with 5 lev-
els of calibrators. The AMR of this test was between 1.0 and 
10,000.0 kU/mL, and the total duration of assay was about 
an hour, including 30 minutes of manual pretreatment with a 
detergent, which exposes HBcrAg.
HBV DNA Quantification and Other Assays
The HBV DNA viral load (IU/mL) was determined by 
using Cobas AmpliPrep/Cobas TaqMan HBV Test, version 
2.0 (Roche Molecular Systems, Pleasanton, CA) accord-
ing to the manufacturer’s instructions. Serum AST and 
ALT levels were measured by using the Hitachi 7600 DDP 
modular chemistry analyzer (Hitachi High-Technologies, 
Tokyo, Japan).
Precision Performance Evaluation
Precision performance of the qHBsAg and HBcrAg 
assays was assessed based on the guidelines from the Clini-
cal and Laboratory Standards Institute document EP4-A2. 
The testing was performed by using a single lot of reagents, 
calibrators, and control samples for each analyzer. For the 
evaluation of the 2 qHBsAg assays, positive quality control 
(QC) material provided by Roche, positive and negative QC 
materials provided by Abbott, and 3 levels of pooled serum 
panels were divided into aliquots and frozen at –20°C. The 
QC materials provided by the manufacturers were assessed to 
evaluate the precision performance of the respective assays. 
Each aliquot was assayed in replicates of 2 at 2 separate times 
per day for 20 days (80 tests per single level) except for the 
negative and positive QC materials for the Architect qHBsAg 
assay, which were tested during 14 and 10 days owing to the 
small sample quantity. In addition, 2 pooled serum samples 
were also tested for HBcrAg in the same manner with the 
evaluation of the qHBsAg assays. All analyzers used a single 
calibration curve throughout the study.
Validation of the Linearity Ranges of the qHBsAg Assays
The tests to validate the linearity of the qHBsAg assays 
were performed based on the Clinical and Laboratory Stan-
dards Institute document EP6-A. Samples with 5 HBsAg 
levels were prepared by mixing high and low levels of pooled 
patient serum samples and were tested in quadruplicate. The 
linearity of the results was assessed by linear regression 
analysis.
Statistical Analysis
All statistical analyses were performed by using Analyse-
it Method Evaluation Edition, version 2.22 software (Analyse-
it Software, Leeds, England). A nonparametric Spearman rank 
test was used to determine the correlation coefficients between 
the levels of HBsAg, HBcrAg, and other indices. All values 
were used without logarithmic transformations. The slope and 
intercept for the linear regressed line between the HBsAg lev-
els by the 2 qHBsAg assays were calculated by using Passing-
Bablok regression analysis. P values of less than .05 were 
considered statistically significant in all analyses.
Results
Precision Performance of the qHBsAg and HBcrAg 
Assays
The precision performance of all evaluated assays is sum-
marized in ❚Table 1❚. The Elecsys qHBsAg assay showed total 
imprecision between 4.5% and 5.3% coefficient of variation 
❚Table 1❚
Precision Performance of the qHBsAg and HBcrAg Assays During 80 Runs for Each Level for a 20-Day Evaluation Period Except 
for QCs of the Architect qHBsAg Assay
  Imprecision, SD (Coefficient of Variation, %)
Analyte/Assay Material Mean Repeatability Between Run Between Day Total
HBsAg (IU/mL)      
   Elecsys QC 0.077 0.003 (3.6) 0.011 (14.3) 0.007 (9.6) 0.014 (17.6)
 PS low 40.603 1.038 (2.6) 0.811 (2.0) 1.285 (3.2) 1.840 (4.5)
 PS medium 4,929.9 93.8 (1.9) 75.8 (1.5) 229.1 (4.9) 258.9 (5.3)
 PS high 11,900.2 223.4 (1.9) 199.4 (1.7) 550.2 (4.6) 626.4 (5.3)
   Architect QC negative* 0.006 0.009 (152.5) 0.000 (0.0) 0.000 (0.0) 0.009 (152.5)
 QC positive† 0.250 0.009 (3.4) 0.003 (1.3) 0.007 (2.7) 0.011 (4.5)
 PS low 38.166 1.419 (3.7) 0.996 (2.6) 0.233 (0.6) 1.749 (4.6)
 PS medium 4,472.9 569.3 (12.7) 0.0 (0.0) 184.5 (4.1) 598.5 (13.4)
 PS high 12,262.5 705.1 (5.8) 293.9 (2.4) 796.7 (6.5) 1,103.8 (9.0)
HBcrAg (kU/mL)      
   Lumipulse PS low 0.13 0.05 (39.8) 0.04 (34.7) 0.00 (2.0) 0.07 (52.9)
 PS high 312.74 9.76 (3.1) 9.06 (2.9) 4.43 (1.4) 14.04 (4.5)
HBcrAg, hepatitis B core–related antigen; HBsAg, hepatitis B surface antigen; PS, pooled serum samples; QC, quality control; qHBsAg, quantitative HBsAg.
* Evaluated during 14 days; analytic sensitivity of this assay, suggested by the manufacturer, is 0.05 IU/mL.
† Assessed during 10 days.
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(CV) for the specimens with mean HBsAg levels of 40.603, 
4,929.9, and 11,900.2 IU/mL, except the QC material with a 
mean HBsAg level of 0.077 IU/mL, for which the impreci-
sion was 17.6% (CV) and 0.014 IU/mL (SD).
The Architect qHBsAg assay also showed imprecision 
less than 5% CV for the positive QC (mean HBsAg, 0.250 
IU/mL) and the low-level serum (mean HBsAg, 38.166 IU/
mL). Imprecision of this assay was 9.0% (CV) for the serum 
with a mean HBsAg level of 12,262.5 IU/mL but was greater 
than 10% (CV) for the pooled serum with a mean HBsAg of 
4,472.9 IU/mL.
The Lumipulse HBcrAg assay also showed total impre-
cision less than 5% for the pooled serum with the mean 
HBcrAg concentration of 312.7 kU/mL. The total impreci-
sion of this assay was 52.9% (CV) and 0.07 kU/mL (SD) for 
serum with a mean HBcrAg of 0.13 kU/mL.
Linearity of the qHBsAg Assays
The linearity of the 2 qHBsAg assays was evaluated by 
testing the serum panel with 5 concentrations in quadrupli-
cate. The measured HBsAg levels by both assays showed 
linear responses to the expected concentrations with an R2 
greater than 0.99. The Elecsys qHBsAg assay was verified 
to be linear in the range between the HBsAg levels of 0.081 
and 12,708.0 IU/mL (linear fit, y = 0.9840x + 1.7730; F = 
8,651.20; P < .0001; R2 = 0.9979), and the linearity of the 
Architect qHBsAg assay was validated from 0.003 to 12,237.9 
IU/mL (linear fit, y = 0.9833x + 11.443; F = 2,204.95; P < 
.0001; R2 = 0.9919), where x means the expected HBsAg 
concentration and y represents the measured HBsAg levels.
Correlation Between the Two qHBsAg Assays
The results obtained with the 2 qHBsAg assays cor-
related well with a correlation coefficient (r) of 0.9934 
(95% confidence interval [CI], 0.9921-0.9944; n = 529; P 
< .0001) ❚Figure 1A❚. However, there were proportional and 
constant biases between the results by the 2 assays, and the 
following equation was established by using Passing-Bablok 
regression:
y = 0.8042x – 110.7340
where x indicates the HBsAg levels by the Architect assay 
and y represents the levels by the Elecsys assay (n = 529) 
❚Figure 1B❚. There was a nonlinear relationship between x 
and y (P < .01). The 95% CI for the proportional bias (slope) 
was between 0.7897 and 0.8195, and that for the constant 
bias (intercept) was from –143.9137 to –88.3642.
Correlation of HBsAg and HBcrAg Levels With Other 
Indices
The correlations for the serum levels of HBsAg, 
HBcrAg, HBV DNA, and aminotransferases are shown 
in ❚Table 2❚. In the 529 specimens included in this study, 
1060.1 1 10 102 103 104 105
Architect HBsAg (IU/mL)
E
le
cs
ys
 H
B
sA
g
 II
 Q
ua
nt
 (I
U
/m
L)
0.1
1
10
102
103
104
105
106
180,000150,0000 30,000 60,000 90,000
Architect HBsAg (IU/mL)
E
le
cs
ys
 H
B
sA
g
 II
 Q
ua
nt
 (I
U
/m
L)
120,000
0
20,000
40,000
60,000
80,000
100,000
120,000
Identity
Passing-Bablok (I) fit
(–110.73 + 0.80x)
95% CI bands
140,000
160,000
180,000
A B
❚Figure 1❚ Correlation between the Elecsys and Architect quantitative hepatitis B surface antigen (HBsAg) assays. A, HBsAg 
levels by the Elecsys HBsAg II Quant assay correlated well with those by the Architect HBsAg QT with a correlation coefficient 
(r) of 0.9934 (95% confidence interval, 0.9921-0.9944; n = 529; P < .0001). Both axes are log scaled. B, There were significant 
proportional and constant biases between the results by the 2 assays, and the following equation was established: y = 0.804x – 
110.734, where x indicates the HBsAg levels by the Architect assay and y represents those by the Elecsys assay.
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the serum HBV DNA levels correlated only weakly with 
HBsAg levels, r = 0.3373 (Elecsys, P < .0001) ❚Figure 2A❚ 
and r = 0.3336 (Architect, P < .0001) ❚Figure 2B❚. No corre-
lation was found between the serum HBsAg concentrations 
determined by the Elecsys qHBsAg assay and the levels of 
aminotransferases (AST, r = –0.0433; P = .3204; ALT, r = 
0.0890; P = .0408).
The serum HBcrAg levels were moderately correlated 
with the HBV DNA levels (r = 0.5198; P < .0001) ❚Figure 3A❚ 
and with HBsAg levels determined by the Elecsys assay (r = 
0.5164; P < .0001) ❚Figure 3B❚. Also, there was a weak cor-
relation between the levels of HBcrAg and aminotransferases 
(AST, r = 0.2371; P < .0001; ALT, r = 0.2698; P < .0001).
Discussion
We evaluated 2 commercially available qHBsAg assays, 
one of which was recently developed specifically for quan-
tification, and a novel newly developed HBcrAg assay. The 
Elecsys qHBsAg assay showed better precision performance 
of around 5% CV for the pooled serum samples at 3 levels 
compared with the Architect qHBsAg assay. Although all 
assays evaluated in our study, including the HBcrAg assay, 
showed a high degree of imprecision of between 17.6% and 
152.5% (CV) for the respective samples with low concentra-
tions, their imprecision would be negligible because the SD 
ranged from only 0.009 to 0.07. In addition, the 2 qHBsAg 
assays showed excellent linearity across HBsAg levels of 
ND <20 102 103 104 105 106 107 108    >1.7×108
HBV DNA Concentration (IU/mL)
E
le
cs
ys
 H
B
sA
g
 II
 Q
ua
nt
 (I
U
/m
L)
0.1
1
10
102
103
104
105
ND <20 102 103 104 105 106 107 108    >1.7×108
HBV DNA Concentration (IU/mL)
A
rc
hi
te
ct
 H
B
sA
g
 (I
U
/m
L)
0.1
1
10
102
103
104
105
A B
❚Figure 2❚ Correlation between serum levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA. A, HBsAg 
levels determined by the Elecsys HBsAg II Quant assay slightly correlated with HBV DNA concentrations (r = 0.3373; 95% 
confidence interval [CI], 0.2695-0.4108; n = 529; P < .0001). B, The levels measured by the Architect HBsAg QT assay also 
showed a similar degree of correlation with HBV DNA levels (r = 0.3336; 95% CI, 0.2556-0.4073; n = 529; P < .0001).
❚Table 2❚
Correlation in Serum Levels of HBsAg, HBcrAg, HBV DNA, and Aminotransferases in 529 Specimens Studied
Assay Comparative Index Correlation Coefficient* (r) (95% CI) P
Elecsys qHBsAg HBV DNA 0.3373 (0.2595 to 0.4108) <.0001
 AST –0.0433 (–0.1281 to 0.0421) .3204
 ALT 0.0890 (0.0037 to 0.1729) .0408
Architect qHBsAg HBV DNA 0.3336 (0.2556 to 0.4073) <.0001
 Elecsys qHBsAg 0.9934 (0.9921 to 0.9944) <.0001
Lumipulse HBcrAg HBV DNA 0.5198 (0.4547 to 0.5793) <.0001
 Elecsys qHBsAg 0.5164 (0.4510 to 0.5763) <.0001
 AST 0.2371 (0.1550 to 0.3159) <.0001
 ALT 0.2698 (0.1889 to 0.3471) <.0001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HBcrAg, hepatitis B core–related antigen; HBsAg, hepatitis B surface antigen; HBV, 
hepatitis B virus; qHBsAg, quantitative HBsAg.
* Correlation coefficients were calculated by using the Spearman rank test.
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between 0.1 and 12,000 IU/mL with an R2 greater than 0.99. 
While the Architect assay should be performed after manual 
dilution of the samples, the Elecsys assay can be carried out 
using the automated predilution after a sample is loaded on 
the analyzer. The manufacturer suggests that the 400-fold 
automated dilution function is installed in the autoanalyzers, 
including Cobas e 601/e 602 and Modular Analytics E170, 
which are different from those used in this study. Therefore, 
the AMR of the Elecsys assays can be between 20 and 52,000 
IU/mL when those analyzers are used, which represents an 
advantage of the Elecsys assay over the Architect assay.
The linearity of HBcrAg was not verified in this study 
because there were insufficient numbers of samples with low 
and high HBcrAg levels. This assay uses calibrators with 5 
levels from 0.0 to 10,000 kU/mL, whereas the 2 qHBsAg 
assays use calibration curves derived from 2 levels of calibra-
tors. The analytic performance of the qHBsAg assays evalu-
ated in this study suggests that they are appropriate for use in 
clinical laboratories, and those of the HBcrAg would need to 
be assessed by further studies. To the best of our knowledge, 
there are no published data regarding the precision perfor-
mance of the HBcrAg assay.
In addition, the new Elecsys qHBsAg assay agreed well 
with the previously developed Architect assay with a high 
correlation of r = 0.9934 for the 529 specimens. Overall, the 
HBsAg levels determined by the Elecsys assay were 0.8-
fold lower than those measured by the Architect assay; this 
difference might be due to the differences in the antibodies 
used to capture the antigen. Two recently published studies 
also reported correlation coefficients of 0.97 and 0.96 between 
the Elecsys and Architect qHBsAg assays.17,18
The HBsAg and HBcrAg levels in our analysis data 
were slightly or moderately correlated with the serum HBV 
DNA levels (Table 2). Both antigens were reported to be 
related to the intrahepatic cccDNA, and cccDNAs serve 
as the template of HBV DNA in the virions. Thus, it is 
plausible that the serum levels of HBV DNA are associated 
with those of the 2 antigens. The levels of HBsAg and HBV 
DNA have also been reported to correlate with each other 
with various correlation coefficients ranging from 0.121 to 
0.862 in several previous studies.2,13,19-23 It is interesting that 
HBsAg and HBV DNA showed lower correlation (r = 0.490) 
in 20 patients with CHB during lamivudine treatment24 and 
correlated better (r = 0.709) in 67 asymptomatic HBV carri-
ers.23 The degree of correlation was also different according 
to the disease stage and HBeAg status.19,20 There was also 
a trend toward decreased correlation according to the dura-
tion of treatment with interferon or nucleoside/nucleotide 
analogs observed in previous studies.13,22 Thus, variation 
in reported correlation coefficients could result from dif-
ferences in disease stage, HBeAg status, HBV genotypes 
involved, and types/phases of treatment. These factors might 
also affect the correlation between the HBcrAg and HBV 
DNA levels. The correlation coefficients between HBcrAg 
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❚Figure 3❚ Correlation of serum hepatitis B core–related antigen (HBcrAg) concentrations with the levels of hepatitis B virus 
(HBV) DNA and hepatitis B surface antigen (HBsAg). A, The levels of HBcrAg and HBV DNA were moderately correlated 
with each other (r = 0.5198; 95% confidence interval [CI], 0.4574-0.5793; n = 529; P < .0001). B, There also was a moderate 
correlation between the serum concentrations of HBcrAg and HBsAg (r = 0.5164; 95% CI, 0.4510-0.5763; n = 529; P < .0001).
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and HBV DNA in patients with CHB were 0.713 (n = 57) 
and 0.927 (n = 50), respectively, in 2 previous studies.15,16 
The degree of correlation between HBcrAg and HBV DNA 
differed according to genotype (r = 0.786 for genotype B, n 
= 21; r = 0.864 for genotype C, n = 169) in another study.25 
In our study, HBcrAg correlated with HBV DNA levels in 
529 specimens (r = 0.5198; P < .0001).
It is interesting that qHBsAg and HBcrAg also correlated 
with each other in our data (r = 0.5164; P < .0001). More-
over, the HBcrAg levels correlated slightly with the serum 
levels of aminotransferases, while the HBsAg levels did not. 
Since there are no published data regarding the correlation 
between qHBsAg and HBcrAg assays, our finding may pro-
vide an indication of a relationship in HBsAg, HBcrAg, and 
HBV DNA levels. Further research with well-defined patient 
groups (eg, treatment phases, HBV genotypes, and HBeAg 
status) would be needed to study the clinical usefulness of 
concurrent testing with qHBsAg and HBcrAg assays.
Unfortunately, we were unable to determine the poten-
tial influence of HBV genotype on correlations between 
the qHBsAg, HBcrAg, and HBV DNA levels in our study. 
However, the most prevalent HBV genotype in Korea is 
C2, which accounted for 98.1% (370/377) of the total HBV 
cases in a recent domestic study.26 Thus, our conclusions 
may be regarded as being drawn from the C2 genotype. In 
a recent study, HBV genotypes did not significantly affect 
the correlation between the 2 qHBsAg assays,17 but further 
research would elucidate the effect of HBV genotype differ-
ences on the correlations in the levels of HBsAg, HBcrAg, 
and HBV DNA.
The qHBsAg and HBcrAg assays evaluated in our study 
showed acceptable analytic performance. In particular, the 2 
qHBsAg assays were shown to have a wide AMR between 
0.1 and 12,000 IU/mL of the HBsAg levels. In our study, the 
HBsAg, HBcrAg, and HBV DNA levels were only slightly to 
moderately correlated with each other, and this could provide 
an indication for the value of further research to elucidate the 
clinical usefulness of qHBsAg and HBcrAg assays.
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